Artículos por temáticas

Impact of prefrontal intermittent theta-burst stimulation on working memory and executive function in Parkinson's disease: A double-blind sham-controlled pilot study

Hill AT, McModie S, Fung W, Hoy KE, Chung SW, Bertram KL.

Brain Res. 2020 Jan 1;1726:146506. doi: 10.1016/j.brainres.2019.146506. Epub 2019 Oct 18.

Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.

Pretegiani E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, Optican LM.

Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861. [Epub ahead of print]

Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL.

Mov Disord. 2020 Jan;35(1):176-180. doi: 10.1002/mds.27876. Epub 2019 Oct 21.

Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.

de Oliveira GAP, Silva JL.

Commun Biol. 2019 Oct 11;2:374. doi: 10.1038/s42003-019-0598-9. eCollection 2019.

Dynamic Alterations of Spontaneous Neural Activity in Parkinson's Disease: A Resting-State fMRI Study.

Zhang C, Dou B, Wang J, Xu K, Zhang H, Sami MU, Hu C, Rong Y, Xiao Q, Chen N, Li K.

Front Neurol. 2019 Oct 1;10:1052. doi: 10.3389/fneur.2019.01052. eCollection 2019.

PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinson's Disease.

Joshi R, Bronstein JM, Keener A, Alcazar J, Yang DD, Joshi M, Hermanowicz N.

Front Neurol. 2019 Oct 1;10:1027. doi: 10.3389/fneur.2019.01027. eCollection 2019.

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.

Goshima Y, Masukawa D, Kasahara Y, Hashimoto T, Aladeokin AC.

Front Pharmacol. 2019 Oct 3;10:1119. doi: 10.3389/fphar.2019.01119. eCollection 2019. Review.

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson's Disease And Schizophrenia.

Gupta AK, Pokhriyal R, Khan MI, Kumar DR, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G.

Neuropsychiatr Dis Treat. 2019 Oct 2;15:2853-2867. doi: 10.2147/NDT.S214217. eCollection 2019.

The impact of traumatic brain injury on cognitive and neuropsychiatric symptoms of Parkinson's disease

Joyce JM, Monchi O, Ismail Z, Kibreab M, Cheetham J, Kathol I, Sarna J, Martino D, Debert CT.

Int Rev Psychiatry. 2020 Feb;32(1):46-60. doi: 10.1080/09540261.2019.1656177. Epub 2019 Oct 21.

Parkinson disease

Balestrino R, Schapira AHV.

Eur J Neurol. 2020 Jan;27(1):27-42. doi: 10.1111/ene.14108. Epub 2019 Nov 27.

Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.

Podlesniy P, Puigròs M, Serra N, Fernández-Santiago R, Ezquerra M, Tolosa E, Trullas R.

EBioMedicine. 2019 Oct 17. pii: S2352-3964(19)30613-9. doi: 10.1016/j.ebiom.2019.09.015. [Epub ahead of print]

Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol J

Alzheimers Dement. 2020 Feb;16(2):292-304. doi: 10.1016/j.jalz.2019.07.018. Epub 2020 Jan 6.

Macular ganglion-cell-complex layer thinning and optic nerve integrity in drug-naïve Parkinson's disease.

Lee JY, Ahn J, Yoon EJ, Oh S, Kim YK, Jeon B.

J Neural Transm (Vienna). 2019 Oct 19. doi: 10.1007/s00702-019-02097-7. [Epub ahead of print]

MRI biomarkers of motor and non-motor symptoms in Parkinson's disease

Ryman SG, Poston KL.

Parkinsonism Relat Disord. 2020 Apr;73:85-93. doi: 10.1016/j.parkreldis.2019.10.002. Epub 2019 Oct 10.

A Study for Therapeutic Treatment against Parkinson’s Disease via Chou’s 5-steps Rule

Lan J, Liu Z, Liao C, Merkler DJ, Han Q, Li J.

Curr Top Med Chem. 2019 Oct 19. doi: 10.2174/1568026619666191019111528. [Epub ahead of print]